Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis
The Journal of Infectious Diseases · 16.12.2024 · 230 (6) · e1287-e1298
DOI: 10.1093/infdis/jiae287 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 10.06.2024. Verfasst von Julie M Strizki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, Antiviral Agents, Valganciclovir. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co, Inc.
Abstract (Originalsprache)
Background
In a phase 3 trial, letermovir was noninferior to valganciclovir for cytomegalovirus (CMV) disease prophylaxis in kidney transplant recipients who were CMV-seronegative and received kidneys from donors who were CMV-seropositive. Genotypic antiviral resistance and CMV glycoprotein B (gB) genotype are reported.
Methods
Plasma samples with detectable CMV DNA were sequenced for the presence of known letermovir and valganciclovir resistance-associated amino acid substitutions (RASs) encoded by CMV gene regions (UL51, UL54, UL56, UL89, UL97) and prevalence of gB (UL55) genotypes (gB1–gB5).
Results
Among participants, 84 of 292 (letermovir) and 93 of 297 (valganciclovir) had evaluable data for ≥1 gene target. Letermovir RASs were not detected in participants who received letermovir prophylaxis; however, 3 had valganciclovir RASs (pUL97). Twelve participants who received valganciclovir prophylaxis had valganciclovir RASs (pUL54, pUL97), and 1 who did not receive letermovir during the trial had letermovir RASs (pUL56). All but 1 participant responded to valganciclovir treatment irrespective of breakthrough CMV DNAemia or frequency of RASs. gB1 was the most frequent genotype across all participants and subgroups.
Conclusions
Letermovir RASs were not detected with letermovir prophylaxis, supporting a low risk for development of resistance in kidney transplant recipients who were CMV-seronegative and received kidneys from donors who were CMV-seropositive. Clinical Trials Registration ClinicalTrials.gov, NCT03443869; EudraCT, 2017-001055-30.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA.
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co, Inc
Zitieren
APA
Strizki, J. M., Diamond, T. L., Teal, V. L., Gilbert, C. L., Wang, W., Stauffer, N., & Haber, B. A. (2024). Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis. The Journal of Infectious Diseases, 230(6), e1287-e1298. https://doi.org/10.1093/infdis/jiae287
Vancouver
Strizki JM, Diamond TL, Teal VL, Gilbert CL, Wang W, Stauffer N, et al. Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis. The Journal of Infectious Diseases. 2024;230(6):e1287-e1298. doi:10.1093/infdis/jiae287
BibTeX
@article{Strizki2024,
author = {Strizki, Julie M and Diamond, Tracy L and Teal, Valerie L and Gilbert, Christopher L and Wang, Weiwen and Stauffer, Nicole and Haber, Barbara A},
title = {Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {6},
pages = {e1287--e1298},
doi = {10.1093/infdis/jiae287}
}
EUVIMED